Transgenic Expression of P1A Induced Thymic Tumor: A Role for Onco-Fetal Antigens in Tumorigenesis by Li, Chi-Shan et al.
Transgenic Expression of P1A Induced Thymic Tumor: A






1Division of Immunotherapy, Section of General Surgery, Department of Surgery, School of Medicine, University of Michigan, Ann Arbor, Michigan, United States of
America, 2Division of Molecular Medicine and Genetics, Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan, United States
of America, 3Program of Molecular Mechanism of Diseases and Comprehensive Cancer Center, School of Medicine, University of Michigan, Ann Arbor, Michigan, United
States of America, 4Department of Pathology, School of Medicine, University of Michigan, Ann Arbor, Michigan, United States of America, 5Toxicology Program,
Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America
Abstract
P1A is the first known tumor rejection antigen. It is expressed in embryonic stem cells and multiple tumors but is silent in
adult tissues except for the testis and placenta. Therefore, P1A represents a prototype for onco-fetal antigens. To test the
potential function of P1A in tumorigenesis, we used a transgenic mouse expressing P1A in lymphoid cells. We observed that
immunodeficient host P1A transgenic mice developed thymic tumors after 7 months of age and had shorter survival rates
compared to control groups. Most of the 7 examined tumors displayed B cell lineage markers. The P1A transgenic bone
marrow cells had higher proliferation ability and more potential progenitors compared to control bone marrow cells. To our
knowledge, our data provided the first example that onco-fetal antigen can promote tumorigenesis.
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Introduction
By definition, tumor antigens were identified because cancer-
reactive lymphocytes could recognize these proteins [1]. An
interesting but still poorly understood phenomenon is that many
tumor antigens are also abundantly expressed at early stages of
embryogenesis. These antigens are termed onco-fetal antigens.
Theoretically, these antigens might be useful for cancer immune
therapy, since they are highly expressed on tumor cells but absent
in the adult host with the exception of placenta and testis. In
addition, the expression of these types of antigens on tumor cells
may reflect the fact that cancer may resemble the biological
properties of embryonic cells. One key issue is whether the onco-
fetal antigens play a significant role in cell differentiation or
proliferation, since tumor and embryonic cells share some
biological properties.
P1A is a prototype of onco-fetal antigens. Only recently, the
P1A gene has been mapped to the X-chromosome (Mouse
Genome Informatics, ID 98818). Identification of P1A as a tumor
rejection antigen marked an important breakthrough in tumor
immunology as it was the first tumor antigen known to be
recognized by cytotoxic T cells [2]. P1A was first identified in the
mastocytoma P815 cell line which was derived from DBA/2 mice
after exposure to methylcholantrene [3]. Later, studies also found
that P1A was expressed in several tumors such as Meth A sarcoma
and J558 plasmacytoma [4]. P1A is highly expressed in the testis
and placenta [5]. The levels of P1A mRNA in the testis and
placenta are around 10–20% and 150–200% of mastocytoma
P815, respectively [5]. In addition, P1A mRNA was detectable in
spleen, lung, liver and thymus by reverse transcription- polymerase
chain reaction (RT-PCR), although the relative abundance of P1A
mRNA in these tissues was much lower than that found in J558
tumor cells [6]. Here, we show that P1A is also expressed in mouse
R1 embryonic stem (ES) cells.
The function of P1A is unknown to date. Since tumor cells,
germ cells and stem cells have the capacity to differentiate and
proliferate, it is possible that P1A may be involved in a particular
state of cell differentiation and growth regulation. Therefore, to
seek the function of onco-fetal antigens, we used P1A as a model.
In this paper, we found that our transgenic mouse line, which
over-expresses tumor antigen P1A in lymphoid cells, developed a
variety of tumors after 7 months. The results from this study
suggest that P1A is involved in tumorigenesis.
Results
P1A express in embryonic stem cells and P1A transgenic
(P1A Tg) thymus
Our P1A transgene contained the enhancer of the immuno-
globulin heavy chain gene (Em), the mb-1 promoter, followed by
P1A open reading frame, an ID2 gene, and an SV40
polyadenylation signal (Figure 1A). P1A was under the control
of the mb-1 promoter, which is expressed specifically in B cells
from the progenitor to mature stages [7]. In addition, the enhancer
of Em has been shown to promote transgene expression in B and T
lymphoid cells [8,9,10,11,12]. Thus, our P1A Tg mice can express
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in P1A Tg thymus by the anti-P1A antibody against the C-
terminus of the P1A protein, however it was not detected in P1A
Tg spleen even with much more protein loaded (Figure 1B). As
shown in Figure 1B, P1A protein level was highest in J558
plasmacytoma cells followed by mouse R1 embryonic stem cells
and then the testis, according to the actin loading amount.
P1A Tg mice developed thymic tumors
To increase tumor susceptibility, we crossed the P1A transgene
to Rag2
2/2 background which is immune-deficient due to lack of
T and B lymphocytes. We observed that 19 out of 49 P1A Tg mice
in Rag2-deficient background developed thymic lymphoma after 7
months of age. The Rag2
2/2P1ATg mice had enlarged thymuses
compared to control mice (Figure 2A). In addition to the thymus,
the spleen was also enlarged (data not shown). Moreover, tumor
infiltration into target organs, including liver and lung, were also
widespread (data not shown). In addition, when using tumor
incidence as a survival end point, P1A Tg mice in immunodefi-
cient background (Rag2
2/2) had significant shorter survival rates
due to the tumor formation compared to control groups
(p=0.0004, Figure 2B). A trend of increased tumor was also
noted in WT background, although the increase was not
statistically significant (p=0.1157, Figure 2C).
In order to determine the lineages of the tumors, we analyzed
the cell surface markers of the thymic tumors. As shown in
Figure 3, only 1 of the 7 tumors analyzed expressed significant
levels of CD4 and CD8. In contrast the majority of tumors
expression markers of non-T lineages, including that of B cells
(B220






+). The result is consistent with the fact
that Rag2 deficiency results in the thymocyte differentiation being
blocked before they can reach the CD4
+CD8
+ stage [13]. It is
noteworthy that all but one of tumors expresses B220, a marker for
the B cell lineage.
P1A Tg bone marrow (BM) cells exhibit higher
proliferation and more hematopoietic colony forming
units
We determined P1A Tg BM cell proliferation ability by BrdU
incorporation assay. BrdU is an analog of the DNA precursor
thymidine. The proliferating cells will incorporate BrdU into their
DNA. The amount of BrdU in the DNA of cells can be detected
with specific anti-BrdU fluorescent antibodies followed by flow
cytometry. After 24 hours of labeling BrdU in vivo, we analyzed
the BrdU incorporation rate by flow cytometry. Forty-six percent
of BM cells from wild-type (WT) control mice were BrdU positive.
However, the P1A Tg mice had a significant increase in the
proportion of BrdU-positive BM cells both in immunocompro-
mised (P1A
+Rag2
+/+) and immunodeficient (P1A
+Rag2
2/2)
backgrounds compared to WT mice (p=0.02 and 0.03, respec-
tively, Figure 4 AB).
We also cultured P1A Tg BM cells and control cells in
methylcellulose based medium to quantify potential progenitors in
vitro. The hematopoietic progenitors were able to proliferate and
differentiate, resulting in the generation of mature cells. Colony-
forming units (CFUs) were measured in semi-solid media with
appropriate cytokines. We found P1A Tg BM had much higher
CFU compared to control BM. The increase was more obvious in
the second round culture (Figure 4C). According to their
morphology, the increases of colony number in all colony types,
including BFU-E (burst-forming unit-erythroid), CFU-G (colony-
forming unit granulocyte), CFU-M (colony-forming unit macro-
phage) and CFU-GM (colony-forming unit granulocyte macro-
phage), were seen in P1A Tg BM by inverted microscopy
(Figure 4D).
Figure 1. Expression of P1A. A. Diagram of Emmb-P1A transgene. P1A open reading frame (P1A-ORF) is under controlled by enhancer of
immunoglobulin heavy chain (Em) and mb-1 promoter (Pmb-1), followed by ID2 gene and an SV40 polyadenylation signal sequence. B. Western blot
analysis of P1A protein expression in J558 plasmacytoma cells, R1 murine ES cells, thymus, spleen, testis from P1A Tg mice and BALB/c WT mice; actin
as internal control.
doi:10.1371/journal.pone.0013439.g001
P1A as an Oncogene
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e13439Discussion
P1A, the first identified tumor rejection antigen, is presented to
cytotoxic T lymphocytes by bound to major histocompatibility
complex (MHC) class I molecules on the tumor cell surface [14].
Our data on the expression of P1A in tumor cells and its presence
in embryonic stem cells and testis indicated that P1A is an onco-
fetal antigen. In testis, it has been shown that P1A expression is
restricted to spermatogonia cells which are MHC class I negative
cells [5]. In addition, MHC class I molecules are not detected in
the undifferentiated ES cells by FACS or immunofluorescence
staining in ES cells [15]. Hence, the low to no expression of cell-
surface MHC class I on spermatogonia and ES cells suggests that
they are immune privilege. Therefore, these normal cells
expressing P1A antigen are compromised in the immune system
due to low MHC class I expression, but not tumor cells.
The phenotypes of P1A Tg mice suggested that onco-fetal
antigen P1A was indeed involved in tumorigenesis. First, we
observed that P1A Tg mice developed thymic leukemia after 7
months of age, particularly in immunocompromised mice. Second,
we demonstrated higher BrdU incorporation in P1A Tg BM cells
compared to WT cells in vivo. Third, there was more CFU from
P1A Tg BM compared to control in vitro. To our knowledge, this
is the first evidence that P1A may promote tumorigenesis, and the
first example that onco-fetal antigen can be involved in
tumorigenesis.
Mice with inactivated Rag2 cannot rearrange lymphocyte antigen
receptors and therefore lack peripheral T cells and B cells [13,16].
In thymus, after TCR-b gene rearrangement, the CD4
2CD8
2
double negative cells differentiate into CD4
+CD8
+ double positive
thymocytes which are selected to single-positive cells (CD4 or CD8)
following TCR-a rearrangement. As a result, T cell development in
Rag2-deficient thymus is arrested prior to the CD4
+CD8
+ stage.
The appearance of a thymic tumor at CD4
+CD8
+ stage suggest that
transformation of T cells may have resulted in expression of the
CD4 and CD8 molecules. The role for P1A in the process is
unknown. Likewise, B cell development in the Rag2-deficient mice
is blocked at the pro-B cell stage which could express cell surface
marker, B220 [13,16]. The widespread expression of B220 among
the tumors is therefore anticipated. However, the occurrence of
thymic tumor in all tumor-bearing mice deserves consideration.
CD4
2CD8
2 double negative thymocytes contain a mixture of
lineage-committed progenitors which can reconstitute T, B, NK
and dendritic cell lineages [17,18,19]. Our transgene P1A was
expressed during hematopoietic progenitor development; therefore,
any stage of cells may be the targets of the transformation or
immortalization process by P1A activation. The heterogeneity was
probably the result of tumor initiation at different stage of
progenitor cell development. Hence, P1A induced tumorigenesis
is not stage-specific and resulted in various thymic tumor types in
mice, such as B cells (B220
+), plasmacytoid dendritic cells
(B220
+CD11c
+) and myeloid cells (Gr1
+CD11b
+).
Figure 2. P1A Tg mice developed tumors. A. Thymus weights of P1A
+Rag2
2/2 mice and Rag2
2/2 mice. Enlarged thymus in P1A
+Rag2
2 mice
after 7 months of age compared to P1A
+Rag2
2 mice. B. P1A
+Rag2
2 mice had shorter survival rates compared to P1A
2Rag2
2 groups. Only mice that
died due to tumor formation were recorded. p=0.0004 (Kaplan-Meier analysis). C. Although several P1A
+Rag2
+ mice died due to tumor formation,
differences in the tumor incidences were not statistical significant. p=0.1157 (Kaplan-Meier analysis).
doi:10.1371/journal.pone.0013439.g002
P1A as an Oncogene
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cancer in immunodeficient background is more frequent
[20,21,22]. For example, children with immunodeficiency are at
a higher risk of malignancy, such as lymphomas and leukemias
[23]. Therefore, the immune system, including innate and
adaptive immunity, is able to inhibit the tumor development
and eradicate the tumors already established [21]. A similar
phenomenon was also shown in animal models. For example, after
subcutaneous injection of the chemical carcinogen methylcholan-
threne, Rag2
2/2 background mice developed higher frequency of
sarcomas compared to the strain-matched controls [24]. Our data
indicated that thymic tumors occurred more frequently in the
Rag2-deficient background and the immune system of a normal
immunocompetent mouse may be able to eliminate the P1A-
induced tumor.
Taken together, P1A induced tumorigenesis and resulted in
various thymic tumor types in mice. Our present work
demonstrated that onco-fetal antigen P1A was associated with
the transformed phenotype in P1A transgenic mice. Therefore,
expression of onco-fetal antigens may be biologically relevant to
tumorigenesis. Further studies are required to dissect the
mechanisms of the process of oncogenesis by P1A.
Materials and Methods
Cell lines and experimental animals
Mouse plasmacytoma J558 from ATCC were cultured in RPMI
1640 medium containing 5% fetal bovine serum (FBS) and 100 mg/
ml penicillin and streptomycin. Murine R1 ES cells were co-cultured
with mouse embryonic fibroblast (MEF) cells in DMEM medium
Figure 3. Heterogeneity of tumors in individual mouse. The thymic tumor from different mice was stained by the following monoclonal
antibodies, CD4, CD8, B220, CD11c, Gr1, and CD11b. After antibody staining, thymic tumor cells were subsequently analyzed by flow cytometry. A.




+ cell populations of tumor cells. B. Mouse #946 had thymic tumor of CD4
+CD8
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+ cell populations of tumor cells. E. Mouse #956 thymic tumor had B220
lo cell population of tumor cells. F.
Mouse #962 had tumor with B220








cell populations of tumor cells.
doi:10.1371/journal.pone.0013439.g003
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3 u/ml
leukemia inhibitory factor, and 4 mM glutamine. Rag2
2/2 mice
were obtained from the Taconic Laboratories (Terrytown, NY). P1A
transgenic (P1A Tg) mice were as described previously [6,9]. The
transgene has been crossed to BALB/c for more than 10 generations,
a n dw a sc r o s s e dt oB A L B / cRag2




All animal experiments were conducted in accordance with accepted
standards of animal care and approved by the Institutional Animal
Care and Use Committee of University of Michigan.
Western blot analysis
Samples of mouse tissues or cells were lysed in protein lysis
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40)
and protease inhibitor cocktails (Sigma) including 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride, aprotinin, bestatin, E-64,
leupeptin and pepstain A were added. Cell lysates were separated
by 10% sodium dodecyl sulphate-polyacrylamide gel electropho-
resis, transferred to polyvinylidene fluoride (PVDF) membranes,
and incubated with anti-P1A rabbit antibody specific for the
peptide sequence, YEMGNPDGFSP (Genemed Synthesis, 1:500
Figure 4. Enhanced proliferation and progenitor activity of P1A Tg bone marrow. A. BrdU incorporation by flow cytometry; representative
profiles of BrdU incorporation in bone marrow cells. B. The proportion of BrdU positive cells among bone marrow cells, showing mean 6 SD of BrdU




2 bone marrow cells. The cells cultured in second round were taken from the first round culture (n=3, two-tailed unpaired
Student’s t-test). D. Higher colony number in all colony types, including burst-forming unit-erythroid (BFU-E), colony-forming unit granulocyte (CFU-
G), colony-forming unit macrophage (CFU-M) and colony-forming unit granulocyte macrophage (CFU-GM), were seen in P1A
+Rag2
2 than in Rag2
2
by inverted microscopy. (n=3, two-tailed unpaired Student’s t-test)
doi:10.1371/journal.pone.0013439.g004
P1A as an Oncogene
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Anti-rabbit or anti-mouse IgG horseradish peroxidase–linked
antibody at 1:3500 dilutions (GE Healthcare) was used as
secondary antibodies. Antibodies were detected with chemilumi-
nescence reaction using the enhanced chemiluminescence kit
(Amersham Biosciences) and visualization with exposure to film.
Flow cytometric analysis
P1A transgenic mice were sacrificed when moribund. Thymus
and spleen tissue were homogenized and passed through a cell
strainer (BD Biosciences) to generate a single-cell suspension. Cells
were stained in phosphate-buffered saline plus 2% FBS for
20 minutes on ice with the following monoclonal antibodies at a
1:200 dilution, CD4, CD8, B220, CD11c, Gr1, and CD11b (BD
Biosciences). Cells were subsequently analyzed by BD LSR II Flow
Cytometer.
Bromodeoxyuridine (BrdU) incorporation assay
Mice were injected intraperitoneally with BrdU (100 mg/kg,
Sigma-Aldrich). Then, mice were given BrdU water (1 mg/ml) for
24 hours before sacrifice. BrdU staining kit (BD Biosciences) was
used according to the manufacturer’s instructions. Each group had
three mice from two independent experiments.
Colony-forming cell assay
Bone marrow cells were isolated from the femur and tibia of
mice. Bone marrow cells (1610
4) were plated in MethoCult
H
methylcellulose-based media (StemCell Technologies) per 35mm
dish and incubated at 37uC, 5% CO2. After 12 days culture,
colony number and morphology was counted using inverted




2/2 mouse and each group was tested in triplicates
from a single experiment.
Statistics
The differences in mouse survival rates were calculated by
Kaplan-Meier analysis. Other data were analyzed using 2-tailed
unpaired Student’s t-test. Differences of p,0.05 were considered
statistically significant. All statistics were performed using Graph-
Pad Prizm, version 5 (GraphPad Software, San Diego, CA).
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